Medical/Pharmaceuticals

Sino Biological ProPure™ Endotoxin-Free Proteins: The "Invisible Guardian" of Biopharmaceuticals

HOUSTON, April 1, 2026 /PRNewswire/ -- After months of meticulous work, your cells suddenly behave unpredictably, or your mouse models develop fever and systemic inflammation during critical studies. The hidden culprit may be endotoxin, the lipopolysaccharide (LPS) from gram-negative bacteria. Ev...

2026-04-01 18:30 3205

PATIENT TRUST AND QUALITY CARE DRIVE MALAYSIA'S GROWING HEALTHCARE REPUTATION

KUALA LUMPUR, Malaysia, April 1, 2026 /PRNewswire/ -- As Malaysia's healthcare ecosystem continues to strengthen its reputation for quality and innovation, Pantai Hospital Kuala Lumpur (PHKL), part of the IHH Healthcare multinational network has been recognised as one of the World's Best Hospital...

2026-04-01 12:16 3089

Abbisko Therapeutics' FGFR4 Inhibitor Irpagratinib Granted Orphan Drug Designation by EMA for Hepatocellular Carcinoma

SHANGHAI, March 31, 2026 /PRNewswire/ -- 31 March 2026, Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256) announced that  its independently developed, highly selective, oral small-molecule FGFR4 inhibitor irpagratinib (ABSK-011), has been granted Orphan Drug Desig...

2026-04-01 10:02 4619

NJ Bio, Inc. and Ajinomoto Bio‑Pharma Services Enter into Collaboration to Strengthen Support for Antibody-Drug Conjugate Development

PRINCETON, N.J. and TOKYO, April 1, 2026 /PRNewswire/ -- NJ Bio, Inc. ("NJ Bio"), a leading provider of integrated drug discovery and development services and Ajinomoto Bio‑Pharma Services ("Aji Bio‑Pharma"), a leading provider of biopharmaceutical manufacturing services and platform technologies...

2026-04-01 07:00 4428

Samsung Biologics completes acquisition of GSK's manufacturing facility in Rockville, Maryland

* Adds 60,000 liters of drug substance capacity, bringing the total to 845,000 liters * Marks Samsung Biologics' geographical diversification and establishes its first U.S. manufacturing presence, expanding regional client support * Plans further investments to add capabilities and strengthe...

2026-03-31 22:00 4850

Dalton Pharma Services Expands Aseptic Powder Fill-Finish Capacity with RoboFil™ system in Toronto

A fully automated aseptic fill-finish platform delivers greater speed, flexibility, and quality for the manufacturing of clinical supplies and commercial products. TORONTO, March 31, 2026 /PRNewswire/ -- Dalton Pharma Services today announced the successful installation of its RoboFil™ aseptic p...

2026-03-31 22:00 3307

Gan & Lee Pharmaceuticals' Once-Weekly Basal Insulin GZR4 Injection Meets Primary Endpoints in Two Pivotal Phase 3 Clinical Trials: SUPER-1 and SUPER-2

BEIJING and BRIDGEWATER, N.J., March 31, 2026 /PRNewswire/ -- Gan & Lee Pharmaceuticals (SSE: 603087) today announced that two pivotal phase 3 clinical trials, SUPER-1 and SUPER-2, evaluating investigative once-weekly insulin GZR4 Injection, have successfully met their pre-specified primary endpo...

2026-03-31 21:50 3950

BON Unveils Strategic Partnership with Tigerbone Group to Launch New Natural Health Initiatives

XI'AN, China, March 31, 2026 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), a leading provider of bio-ingredient solutions in the natural, health, and personal care industries, announced today that on February 4, 2026 it entered into a Cooperation Framework Agree...

2026-03-31 21:00 4198

Co-PSMA data published in the European Urology journal

SYDNEY, March 31, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the results fro...

2026-03-31 20:58 3854

Inaugural Rabies in Asia Conference to Be Held in Kuching

KUCHING, Malaysia, March 31, 2026 /PRNewswire/ -- Place Borneo Sdn Bhd, in collaboration with the Department of Veterinary Services Sarawak (DVSS), will host the 1st Rabies in Asia (RIA) 2026 in conjunction with the 5th Rabies in Borneo (RIB) 2026, taking place 29 September to 1 October 2026 at t...

2026-03-31 20:31 3591

LabConnect Launches SampleGISTICS® 2.0 to Digitize Clinical Trial Sample Capture

Smartphone-based solution streamlines site workflows and enables real-time visibility at the sample level RALEIGH, N.C., March 31, 2026 /PRNewswire/ -- LabConnect

2026-03-31 20:15 2363

3SBio Announces 2025 Annual Results: Dual Engines of Innovative R&D and Global Collaboration Propel Revenue Past RMB 10 Billion Milestone

SHANGHAI, March 31, 2026 /PRNewswire/ -- 3SBio Inc. (01530.HK ) today released its 2025 annual results announcement. Fueled by the dual core engines of breakthroughs in innovative R&D and strategic global collaboration, the company delivered a high-quality performance with bot...

2026-03-31 20:13 6495

Diagens Biotechnology Raises US$101 Million in Hong Kong IPO; Shares More Than Double on First Day of Trading

Public offering oversubscribed 1,073 times as medical imaging AI company debuts on HKEX HANGZHOU, China, March 31, 2026 /PRNewswire/ -- Hangzhou Diagens Biotechnology Co., Ltd. (HKEX: 02526) today began trading on the Main Board of The Stock Exchange of Hong Kong. Shares closed at HK$202.60, up ...

2026-03-31 18:34 5349

Ivonescimab Shows Quality of Life Benefits in Chemotherapy-Free First-Line NSCLC: Health-Related Quality of Life Data from the HARMONi-2 Study Presented at ELCC 2026

HONG KONG, March 31, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK)  ("Akeso" or the "Company") announced the results of health-related quality of life (HRQoL) data (Poster: 107P) from the HARMONi-2 study at the 2026 European Lung Cancer Congress (ELCC). The study evaluated ivonescimab, the company's...

2026-03-31 17:40 3867

SirPAD: Primary Results confirm the safety and efficacy of Sirolimus Coated Balloon in PAD

TAMPA, Fla., March 31, 2026 /PRNewswire/ -- Concept Medical Inc. (CMI), a global leader in innovative drug-delivery technology across vascular interventions, proudly announces the presentation of the world's largest randomised controlled trial of a Sirolimus-coa...

2026-03-31 16:27 3692

DNV SELECTED TO CERTIFY CLASS D DEVICES FOR LEADING U.S. MANUFACTURER UNDER EU IVDR

DNV supports the manufacturer's transition to new regulation with its digital certification platform and transparent, predictable project management. OSLO, Norway, March 31, 2026 /PRNewswire/ -- DNV, a designated Notified Body for the European Union's In Vitro Diagnostic Regulation (IVDR) and Med...

2026-03-31 15:00 4346

Abbisko Therapeutics' FGFR2/3 Inhibitor ABSK061 Receives FDA IND Clearance for Achondroplasia in Children

SHANGHAI, March 31, 2026 /PRNewswire/ -- On 30 March, 2026, Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) announced thatthe U.S. Food and Drug Administration has cleared the Investigational New Drug (IND) application for ABSK061, a highly selective small-...

2026-03-31 14:10 3936

NAVER D2SF Makes Follow-On Investment in Soundable Health, an AI-Driven Health Tech Startup Scaling in the U.S. Market

SEOUL, South Korea, March 30, 2026 /PRNewswire/ -- NAVER D2SF, the corporate venture capital arm of NAVER, has made a follow-on investment in Soundable Health, a health tech startup leveraging AI-powered acoustic analysis to enable clinical-grade diagnostics through everyday devices. Having parti...

2026-03-31 08:30 4583

Innovent's Partner Ollin Biosciences Announces Final Data from Randomized Head-to-Head Study of IBI324 Compared to Faricimab (Vabysmo) in Wet Age-Related Macular Degeneration and Diabetic Macular Edema

* OLN324 demonstrated meaningfully faster and greater improvements in anatomic outcomes in DME and numerically greater vision gains sustained through 20 weeks with fewer retreatments as compared to faricimab * New anatomic data demonstrates OLN324 achieves faster, greater, and more durable re...

2026-03-31 08:00 4466

4DMedical receives CE Mark for CT:VQ™, enabling commercial launch across the European Union

In a separate announcement made today, the Company also secured A$83 million in private placement funding to support growth initiatives, including European expansion. MELBOURNE, Australia, March 31, 2026 /PRNewswire/ -- 4DMedical Limited (ASX:4DX), the global leader in cardiothoracic imaging s...

2026-03-31 05:20 4491
1 ... 19202122232425 ... 649